These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26553770)

  • 1. Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?
    Kaklamani VG; Gradishar WJ
    J Natl Compr Canc Netw; 2015 Nov; 13(11):1448-52. PubMed ID: 26553770
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA advisory panel recommends approval of drug for preoperative treatment of breast cancer.
    Jin J
    JAMA; 2013 Oct; 310(14):1434. PubMed ID: 24104359
    [No Abstract]   [Full Text] [Related]  

  • 3. Pertuzumab (Perjeta) for preoperative use in HER2-positive breast cancer.
    Med Lett Drugs Ther; 2013 Dec; 55(1431):98-9. PubMed ID: 24322664
    [No Abstract]   [Full Text] [Related]  

  • 4. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
    O'Sullivan CC; Connolly RM
    Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant trials could speed up drug approvals.
    Peres J
    J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
    [No Abstract]   [Full Text] [Related]  

  • 6. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
    Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer.
    Esposito A; Criscitiello C; Curigliano G
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):51-5. PubMed ID: 26063887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avastin saga reveals debate over clinical trial endpoints.
    Sharma SP
    J Natl Cancer Inst; 2012 Jun; 104(11):800-1. PubMed ID: 22673590
    [No Abstract]   [Full Text] [Related]  

  • 9. Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.
    Dawood S; Sirohi B
    Future Oncol; 2015; 11(6):923-31. PubMed ID: 25760974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant therapy as a platform for drug development and approval in breast cancer.
    Bardia A; Baselga J
    Clin Cancer Res; 2013 Dec; 19(23):6360-70. PubMed ID: 24298066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant pertuzumab: the exception that proves the rule?
    Burstein HJ
    Oncology (Williston Park); 2014 Mar; 28(3):197-9. PubMed ID: 24855726
    [No Abstract]   [Full Text] [Related]  

  • 12. [New approaches to the treatment of breast cancer].
    Semiglazov VF
    Vopr Onkol; 2013; 59(3):288-91. PubMed ID: 23909027
    [No Abstract]   [Full Text] [Related]  

  • 13. Ado-trastuzumab emtansine approved for advanced breast cancer.
    Traynor K
    Am J Health Syst Pharm; 2013 Apr; 70(7):562. PubMed ID: 23515502
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of Anti-HER-2 Therapies in the Neo-Adjuvant Setting: Is Complete Pathological Response a Solid Surrogate?
    Valsecchi ME; Díaz-Cantón E
    Rev Recent Clin Trials; 2015; 10(2):82-9. PubMed ID: 26216436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant pertuzumab improves early breast cancer outcomes.
    Das M
    Lancet Oncol; 2017 Jul; 18(7):e378. PubMed ID: 28625555
    [No Abstract]   [Full Text] [Related]  

  • 16. [DCIS and HER2/neu].
    Tulusan AH
    Onkologie; 2002 Dec; 25 Suppl 5():11-2; discussion 13. PubMed ID: 23573612
    [No Abstract]   [Full Text] [Related]  

  • 17. Pertuzumab: increasing the options.
    Nunes R; Swain SM
    Oncology (Williston Park); 2014 Mar; 28(3):199, 204, 210. PubMed ID: 24855727
    [No Abstract]   [Full Text] [Related]  

  • 18. [Strategies of breast cancer treatment based on determination of biological subtype].
    Semiglazov VF
    Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
    [No Abstract]   [Full Text] [Related]  

  • 19. Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2012 Jul; 54(1395):59-60. PubMed ID: 22825690
    [No Abstract]   [Full Text] [Related]  

  • 20. Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting.
    Kalinsky K; Hershman DL
    J Comp Eff Res; 2013 Jul; 2(4):393-403. PubMed ID: 24236681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.